During Q4 2024, global stocks were pressured by investor concerns about economic growth and persistent inflation in some regions & despite potential for further interest rate cuts in 2025.

Shares of Elevance Health Inc. ELV slipped 1.42% to $405.40 Tuesday, on what proved to be an all-around great trading session ...

StockNews.com cut shares of Elevance Health (NYSE:ELV – Free Report) from a buy rating to a hold rating in a research note ...

Investment analysts at Leerink Partnrs dropped their Q3 2025 EPS estimates for shares of Elevance Health in a research note ...

Shares of Elevance Health Inc. ELV shed 1.26% to $400.30 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.47% to 6,039.31 ...

Before making this announcement, Elevance Health was easily earning enough to cover the dividend. As a result, a large proportion of what it earned was being reinvested back into the business.

Analysts' ratings for Elevance Health ELV over the last quarter vary from bullish to bearish, as provided by 6 analysts. Summarizing their recent assessments, the table below illustrates the ...

Whit Mayo, an analyst from Leerink Partners, reiterated the Buy rating on Elevance Health (ELV – Research Report). The associated price target is $463.00. Whit Mayo has given his Buy rating due ...

In a report released today, Stephen Baxter from Wells Fargo maintained a Buy rating on Elevance Health (ELV – Research Report), with a price target of $478.00. The company’s shares closed ...

Unless the payments are sustainable, the dividend yield doesn't mean too much. Before making this announcement, Elevance Health was easily earning enough to cover the dividend. As a result, a large ...